Advertisement
Advertisement
TRAX
T
First Tracks Biotherapeutics, Inc. Ordinary Shares
16.69
USDSponsored
-1.09
-6.13%
Jun 24, 16:00 UTC -4
Closed
Pre-Market
16.11
-0.58
-3.48%
TRAX Earnings Reports
Positive Surprise Ratio
TRAX beat 0 of 1 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
First Tracks Biotherapeutics, Inc. Ordinary Shares earnings per share and revenue
On May 14, 2026, TRAX reported earnings of -1.45 USD per share (EPS) for Q1 26, missing the estimate of -0.53 USD, resulting in a -172.35% surprise. Revenue reached --, compared to an expected 4.54 million, with a -100.00% difference. The market reacted with a -6.94% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Odyssey Therapeutics, Inc. Common Stock
Report Date
Jun 17, 2026 For Q1 26
Estimate
-$1.27
Actual
-$6.77
Surprise
-429.90%
Aimei Health Technology Co., Ltd Ordinary Share
Report Date
Jun 16, 2026 For Q1 26
Estimate
-Actual
$0.01
Surprise
-
Suncrete, Inc. Class A Common Stock
Report Date
Jun 24, 2026 For Q1 26
Estimate
$0.04
Actual
-$0.06
Surprise
-247.06%
Aimei Health Technology Co., Ltd Unit
Report Date
Jun 16, 2026 For Q1 26
Estimate
-Actual
$0.01
Surprise
-
Cerebras Systems Inc. Class A Common Stock
Report Date
Jun 23, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.04
Surprise
+75.67%
Sunbelt Rentals Holdings, Inc.
Report Date
Jun 23, 2026 For Q4 26
Estimate
$0.75
Actual
$0.74
Surprise
-2.54%
Fervo Energy Company Class A common stock
Report Date
Jun 22, 2026 For Q1 26
Estimate
-$0.07
Actual
-$3.72
Surprise
-5169.12%
HawkEye 360, Inc.
Report Date
Jun 22, 2026 For Q1 26
Estimate
-$0.05
Actual
-$0.44
Surprise
-684.31%
FAQ
What were First Tracks Biotherapeutics, Inc. Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, First Tracks Biotherapeutics, Inc. Ordinary Shares reported EPS of -$1.45, missing estimates by -172.35%, and revenue of $0.00, -100% below expectations.
How did the market react to First Tracks Biotherapeutics, Inc. Ordinary Shares's Q1 2026 earnings?
The stock price moved down -6.94%, changed from $18.16 before the earnings release to $16.90 the day after.
When is First Tracks Biotherapeutics, Inc. Ordinary Shares expected to report next?
The next earning report is scheduled for --.
What are the forecasts for First Tracks Biotherapeutics, Inc. Ordinary Shares's next earnings report?
Based on --
analysts, First Tracks Biotherapeutics, Inc. Ordinary Shares is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement